<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-05-21T05:59:34.205Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Kidney J</journal-id><journal-id journal-id-type="iso-abbrev">Clin Kidney J</journal-id><journal-id journal-id-type="publisher-id">ckj</journal-id><journal-title-group><journal-title>Clinical Kidney Journal</journal-title></journal-title-group><issn pub-type="ppub">2048-8505</issn><issn pub-type="epub">2048-8513</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400789</article-id><article-id pub-id-type="pmc">PMC12092915</article-id><article-id pub-id-type="doi">10.1093/ckj/sfaf141</article-id><article-id pub-id-type="publisher-id">sfaf141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="category-toc-heading"><subject>Dialysis</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00340</subject></subj-group></article-categories><title-group><article-title>Effectiveness of blood volume change&#x02013;guided ultrafiltration control (BV-UFC) in hemodialysis: a crossover comparative study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-0936-2259</contrib-id><name><surname>Hamada</surname><given-names>Shintaro</given-names></name><!--hamashin7650@gmail.com--><aff>Department of Nephrology, <institution>Sanin Rosai Hospital</institution></aff><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Hata</surname><given-names>Masami</given-names></name><aff>Department of Clinical Engineer, <institution>Sanin Rosai Hospital</institution></aff></contrib><contrib contrib-type="author"><name><surname>Furukawa</surname><given-names>Shuntaro</given-names></name><aff>Department of Clinical Engineer, <institution>Sanin Rosai Hospital</institution></aff></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Sunao</given-names></name><aff>Department of Nephrology, <institution>Sanin Rosai Hospital</institution></aff></contrib></contrib-group><author-notes><corresp id="cor1">Correspondence to: Shintaro Hamada; E-mail: <email>hamashin7650@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-05-06"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>06</day><month>5</month><year>2025</year></pub-date><volume>18</volume><issue>5</issue><elocation-id>sfaf141</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="corrected-typeset"><day>15</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of the ERA.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="sfaf141.pdf"/><abstract><title>ABSTRACT</title><sec id="abs1"><title>Background and hypothesis</title><p>Intradialytic hypotension (IDH), a common hemodialysis (HD) complication, increases cardiovascular risks and affects prognosis. Rapid ultrafiltration (UF) is a key factor. The blood volume change&#x02013;guided ultrafiltration control (BV-UFC) system, which adjusts UF rates based on real-time blood volume (BV) monitoring, aims to enhance hemodynamic stability and reduce IDH.</p></sec><sec id="abs2"><title>Methods</title><p>A 6-week crossover trial compared BV-UFC and standard HD in reducing IDH. Patients underwent 2&#x000a0;weeks of each treatment. The primary outcome was the frequency of IDH episodes. Secondary outcomes were plasma refilling rate (PRR) and target UF volume achievement.</p></sec><sec id="abs3"><title>Results</title><p>This study included 38 patients, with 31 patients completing the trial. The frequency of IDH episodes was significantly reduced in patients using the BV-UFC system (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.019). HD sessions with BV-UFC system showed a significantly higher PRR throughout the treatment session, particularly during the first 0&#x02013;1&#x000a0;h and 1&#x02013;2&#x000a0;h of treatment (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.019, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001), as compared with standard HD and the target UF volume was consistently higher in the BV-UFC sessions (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.01).</p></sec><sec id="abs4"><title>Conclusion</title><p>The BV-UFC system effectively reduced the incidence of IDH by automatically adjusting the UF rate based on BV, without compromising treatment safety or UF volume. These findings suggest that BV-UFC can enhance hemodynamic stability and improve dialysis outcomes in patients undergoing HD (jRCT Study No. jRCT1062230034, registration date: 1 July 2023).</p></sec></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1"><label>Graphical Abstract</label><graphic xlink:href="sfaf141fig1g" position="float"/></fig>
</p></abstract><kwd-group><kwd>blood volume change-guided ultrafiltration control</kwd><kwd>hemodialysis</kwd><kwd>intradialytic hypotension</kwd><kwd>plasma refilling</kwd></kwd-group><counts><page-count count="12"/></counts></article-meta></front><body><boxed-text position="float"><label>KEY LEARNING POINTS</label><p>
<bold>What was known:</bold>
</p><list list-type="bullet"><list-item><p>Intradialytic hypotension (IDH) is a frequent complication during hemodialysis, leading to cardiovascular risks.</p></list-item><list-item><p>Blood volume (BV) monitoring has shown potential in improving hemodynamic stability by adjusting ultrafiltration rates, but the effectiveness of BV change&#x02013;guided ultrafiltration control (BV-UFC) systems had not been conclusively proven.</p></list-item></list><p>
<bold>This study adds:</bold>
</p><list list-type="bullet"><list-item><p>This study demonstrates that BV-UFC significantly reduces the incidence of IDH by automatically adjusting the ultrafiltration rate in response to real-time BV changes, without compromising treatment safety.</p></list-item><list-item><p>Hemodialysis sessions with BV-UFC also show improved plasma refilling rates and target ultrafiltration volume achievement.</p></list-item></list><p>
<bold>Potential impact:</bold>
</p><list list-type="bullet"><list-item><p>The BV-UFC system enhances hemodynamic stability during hemodialysis, potentially reducing the risk of cardiovascular events associated with IDH.</p></list-item><list-item><p>This technology could improve dialysis outcomes and patient safety, paving the way for broader adoption in clinical practice to manage fluid balance more effectively.</p></list-item></list></boxed-text><sec sec-type="intro" id="sec2"><title>INTRODUCTION</title><p>Intradialytic hypotension (IDH) presents a substantial challenge in the management of patients undergoing hemodialysis (HD) [<xref rid="bib1" ref-type="bibr">1</xref>]. This complication, characterized by a critical drop in blood pressure (BP) during dialysis sessions, not only compromises the efficiency of the HD procedure but also poses serious risks of cardiovascular events and long-term outcomes [<xref rid="bib2" ref-type="bibr">2&#x02013;4</xref>]. An increased risk of IDH is associated with several patient-related characteristics and comorbidities including advanced age, diabetes mellitus, ischemic heart disease, left ventricular hypertrophy and autonomic dysfunction [<xref rid="bib5" ref-type="bibr">5&#x02013;7</xref>]. These factors contribute to heightened susceptibility to IDH by disrupting compensatory mechanisms, thereby impairing cardiovascular stability during HD. Rapid ultrafiltration (UF) rates have been shown to negatively impact survival outcomes [<xref rid="bib8" ref-type="bibr">8</xref>], whereas fluid overload is associated with poor prognosis [<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>]. Excessive UF during HD often causes IDH due to insufficient plasma refilling from the interstitial to capillary circulation. Rapid fluid removal exceeds the vascular system's capacity to replenish plasma, leading to reduced blood volume (BV), hypotension, and compromised hemodynamic stability, which can worsen patient morbidity [<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>]. Prolonged dialysis has been shown to improve the prognosis by enabling adequate UF and lowering the UF rate [<xref rid="bib13" ref-type="bibr">13</xref>]. However, this approach imposes a greater burden on the HD patients and staff. A key challenge in HD therapy is achieving the same UF volume within the same treatment timeframe, while avoiding IDH and improving patient outcomes.</p><p>Recent advancements in dialysis technology have enabled non-invasive and highly accurate monitoring of BV in HD devices [<xref rid="bib14" ref-type="bibr">14&#x02013;16</xref>]. Continuous BV monitoring has been reported as a potential method for early detection of hemodynamic changes associated with IDH [<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>]. Using an intradialytic BV monitoring (IBVM) device, UF rates were manually adjusted based on BV monitoring during the CLIMB trial. However, this approach was associated with increased hospitalization and mortality rates compared with standardized monitoring [<xref rid="bib19" ref-type="bibr">19</xref>]. These findings suggest that manually adjusting UF rates based on BV monitoring presents significant challenges for dialysis staff and may not effectively mitigate adverse outcomes. In contrast, dialysis devices by Nikkiso Co., Ltd (Tokyo, Japan) feature a BV change&#x02013;guided ultrafiltration control (BV-UFC) system that adjusts automatically the UF rate every 2&#x000a0;min based on BV measurements, following a target BV reduction curve. This system theoretically aligns UF rates with plasma refilling, reducing IDH incidence. However, a previous crossover trial showed no significant difference in IDH incidence between standard HD and HD with the BV-UFC system [<xref rid="bib20" ref-type="bibr">20</xref>]. A previous study used a BV-UFC system with near-default settings, though these are not always straightforward to use. In this study, we conducted a crossover trial to examine hemodynamic responses during HD after modifying BV-UFC settings to simplify configuration.</p></sec><sec sec-type="materials|methods" id="sec3"><title>MATERIALS AND METHODS</title><sec id="sec3-1"><title>Subjects</title><p>Outpatients undergoing HD in our hospital who met the following criteria were enrolled: (i) 20&#x000a0;years &#x000a0;&#x02264;&#x000a0;age&#x000a0;&#x02264;&#x000a0;90&#x000a0;years; (ii) can get a blood flow rate of 200&#x000a0;mL/min or more by vascular access; and (iii) have been receiving HD for at least 3&#x000a0;months before study enrollment. Pregnancy and vascular access recirculation were excluded. The patients were randomly assigned into two groups in an open-label design with R (The R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec id="sec3-2"><title>Study design</title><p>We conducted a 6-week crossover intervention study to observe hemodynamics in patients undergoing HD. The study consisted of a 2-week run-in period, followed by a 2-week standard HD, and then another 2-week HD with BV-UFC. A multipurpose dialysis-monitoring device DCS-200Si (Nikkiso, Tokyo, Japan) was used throughout all study periods. Patient recruitment was performed from 1 June 2023, to 1 February 2024. This study was conducted between 1 August 2023, and 30 May 2024.</p></sec><sec id="sec3-3"><title>Definitions</title><p>BP was measured at the start of HD and every 20&#x000a0;min using an electronic monitor. IDH was defined as a drop in systolic BP of &#x02265;20&#x000a0;mmHg or mean arterial pressure (MAP) of &#x02265;10&#x000a0;mmHg from baseline [<xref rid="bib21" ref-type="bibr">21</xref>].</p><p>Treatments for symptomatic IDH (e.g. nausea, dizziness, cramps) included adjusting the bed to the Trendelenburg position, modifying UF rate (standard HD only), administering oral peony licorice solution and saline infusion.</p></sec><sec id="sec3-4"><title>Run-in period</title><p>The dry weight in each facility was determined using various methods, including physical assessments, hemodynamic status during HD, cardiothoracic ratio measured by chest X-ray, post-HD human atrial natriuretic peptide levels, and the degree of %&#x00394;BV reduction by a multidisciplinary team consisting of nephrologists, nurses and clinical engineers. To appropriately achieve dry weight in HD with BV-UFC, BV-UFC settings were established during a 2-week run-in period for each enrolled patient and remained unchanged throughout the crossover study period. During this 2-week period, the lower limit alarm for systolic BP was set between 110 and 130&#x000a0;mmHg for each patient, as is customary in regular dialysis practice (Fig.&#x000a0;<xref rid="fig1" ref-type="fig">1</xref>).</p><fig position="float" id="fig1"><label>Figure 1:</label><caption><p>Flow diagram of the study. This figure illustrates the study design, including the 6-week study period, initial 2-week run-in phase, and subsequent 4-week crossover period. Patient randomization and group assignments for standard HD and HD with BV-UFC are shown.</p></caption><graphic xlink:href="sfaf141fig1" position="float"/></fig></sec><sec id="sec3-5"><title>UF rate setting during HD with the BV-UFC system</title><p>HD with BV-UFC was divided into four phases based on changes in the UF rate. The default settings were as follows: (i) constant UF rate for the first 10&#x000a0;min, calculated as body weight gain divided by HD time (constant UF rate period); (ii) 1.3&#x000a0;&#x000d7;&#x000a0;higher UF rate for the next 60&#x000a0;min (higher UF rate period); (iii) automatic UF adjustments based on &#x00394;BV every 2&#x000a0;min until 20&#x000a0;min before HD completion, targeting reductions of 50%, 80% and 95% (automatic UF rate&#x02013;adjustment period); and (iv) constant UF rate in the final 20&#x000a0;min to reach dry weight (automatic constant UF rate period). Adjustments were made to time intervals, UF rates and target %&#x00394;BV; however, default settings had issues, including excessively high UF rates if patients exceeded dry weight, challenging &#x00394;BV targets and large UF rates at the end. To address this, we shortened the second phase to 10&#x000a0;min with a 1.0&#x000a0;&#x000d7;&#x000a0;UF rate, set the target %&#x00394;BV of the third phase to 2%&#x02013;4% higher than that at the end of standard HD in the third phase, and reduced the UF rate to 50% of the remaining UF volume for the final 20&#x000a0;min in the fourth phase. The length of the third phase was determined by subtracting the total duration of the first, second, and fourth phases (a total of 40&#x000a0;min) from the total dialysis time. For example, if the total dialysis time is 240&#x000a0;min, the third part corresponds to 200&#x000a0;min (Table&#x000a0;<xref rid="tbl1" ref-type="table">1</xref>).</p><table-wrap position="float" id="tbl1"><label>Table 1:</label><caption><p>BV-UFC settings.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="4" rowspan="1">BV-UFC settings</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Default settings</th><th align="center" colspan="2" rowspan="1">This study</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Times (min)</th><th rowspan="1" colspan="1">UF rate (%)</th><th rowspan="1" colspan="1">Times (min)</th><th rowspan="1" colspan="1">UF rate (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Constant UF rate period (1st part)</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">100</td></tr><tr><td rowspan="1" colspan="1">Higher UF rate period (2nd part)</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">100</td></tr><tr><td rowspan="1" colspan="1">Automatic UF rate adjustment period (3rd part)</td><td rowspan="1" colspan="1">HD time: 90 min</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">HD time: 40 min</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Automatic constant UF rate period (4th part)</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">50</td></tr></tbody></table><table-wrap-foot><fn id="tb1fn1"><p>This table compares the default settings of the BV-UFC system with the settings used in this study. The time duration and UF rate for each phase&#x02014;constant UF rate period (1st part), higher UF rate period (2nd part), automatic UF rate adjustment period (3rd part) and automatic constant UF rate period (4th part)&#x02014;are indicated.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-6"><title>Crossover study period</title><p>During this period, patients in Group A underwent standard HD for 2&#x000a0;weeks, followed by 2&#x000a0;weeks of HD with BV-UFC. Group B patients underwent HD with BV-UFC for 2&#x000a0;weeks, followed by 2&#x000a0;weeks of standard HD. All participants in this study underwent HD three times per week. This crossover comparative study included a total of 12 HD sessions for each participant: 6 sessions over 2&#x000a0;weeks with standard HD and 6 sessions over 2&#x000a0;weeks with BV-UFC-guided HD. During the 4-week period, each patient underwent a crossover between standard HD and HD with BV-UFC, with no changes in dry weight, antihypertensive medication or BV-UFC settings. Data from 12 HD sessions over a 4-week period were collected.</p></sec><sec id="sec3-7"><title>Primary outcome</title><p>The primary outcome was differences in the number of IDH episodes between the two conditions.</p><p>The number of IDH episodes per HD session was evaluated using BP measurements every 20&#x000a0;min.</p></sec><sec id="sec3-8"><title>Secondary outcomes</title><list list-type="simple"><list-item><label>(i)</label><p>The average plasma refilling rate (PRR)</p></list-item></list><p>The average plasma refilling rate was evaluated to assess hemodynamics during HD.</p><p>PRR was calculated using the following formula:</p><disp-formula>
<tex-math id="TM0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*}
{\mathrm{PRR}} = {\mathrm{\ }}\frac{{{\mathrm{UF\ volume\ during\ the\ measurement\ period}} + {\mathrm{\Delta BV}}\left( {{\mathrm{increase\ in\ blood\ volume\ during\ the\ measurement\ period}}} \right)}}{{{\mathrm{Duration\ of\ the\ measurement\ period}}}}
\end{equation*}\end{document}</tex-math>
</disp-formula></sec><sec id="sec3-9"><title>Detailed explanation</title><p>UF volume during the measurement period: the ultrafiltration volume (in mL) removed by the dialysis machine during the measurement period; &#x00394;BV(increase in BV during the measurement period): calculated using the &#x00394;BV change rate during the measurement period; duration of the measurement period: each measurement period was fixed at 60&#x000a0;s (1&#x000a0;min).</p><p>The initial BV at the start of each dialysis session is automatically estimated using pre-dialysis body weight (kg)/13. The average PRR (L/h) was recorded every 20&#x000a0;s using the DCS-200Si device during the entire dialysis session. The values were adjusted for each patient's dry weight (kg) to calculate the average PRR (mL/kg/h). PRR values were then averaged for the following intervals: the entire HD session, 0&#x02013;1&#x000a0;h, 1&#x02013;2&#x000a0;h, 2&#x02013;3&#x000a0;h and 3&#x02013;4&#x000a0;h after dialysis initiation.</p><p>The PRR values during the first 16&#x000a0;min after HD initiation were excluded from the analysis because of potential instability caused by pre-HD walking and infusion of priming saline into the body.</p><list list-type="simple"><list-item><label>(ii)</label><p>Achievement rate of target UFV</p></list-item></list><p>Achievement of the target ultrafiltration volume (UFV) at the end of HD was defined as being within&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;kg of the dry weight.</p><list list-type="simple"><list-item><label>(iii)</label><p>Number of treatment episodes for IDH</p></list-item></list><p>The frequency of operations and interventions performed by the medical staff during HD included rapid adjustment of the dialysis bed to the Trendelenburg position, modification of the UF rate (in standard HD only), saline infusion, and lower limit alarms for systolic BP.</p></sec><sec id="sec3-10"><title>Statistical analyses</title><p>Data on patients&#x02019; general characteristics are presented as mean&#x000a0;&#x000b1;&#x000a0;SD, calculated from the averages of all patients included in the study. Clinical data from standard HD and HD with BV-UFC are presented as mean&#x000a0;&#x000b1;&#x000a0;standard error, based on the mean values of all hemodialysis sessions conducted during the study period for each patient. This approach ensures that the results reflect overall trends across sessions rather than individual session variability. Paired t-tests were used to compare clinical parameters between HD and HD patients with BV-UFC. The chi-square test was used to the number of dialysis sessions which at least one hypotensive event (systolic blood pressure decrease more than 20&#x000a0;mmHg). McNemar's test was used to evaluate the achievement rate of the target UF volume at the end of HD. All analyses were performed using StatFlex ver7 (Artech Co., Osaka, Japan). Statistical significance was set at <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.05. The 95% confidence intervals (CI) were calculated using the model parameter coefficients and standard error (SE).</p><p>This study did not apply an intention-to-treat (ITT) analysis, as seven participants withdrew before receiving any treatment (five did not start the crossover trial, and two discontinued before initiating either standard HD or BV-UFC). Therefore, a per-protocol analysis was performed, including only participants who completed the trial.</p></sec><sec id="sec3-11"><title>Ethical approval</title><p>This study was registered in the Japan Registry of Clinical Trials (jRCT Study No. jRCT1062230034, registration date: 1 July 2023) and was approved by the Ethics Committee of Sanin Rosai Hospital (approval number: 11&#x02009;000&#x02009;999). The study was conducted in accordance with the principles outlined in the Declaration of Helsinki (Fortaleza, 2013). Informed consent was obtained from all participants prior to their enrollment in the study.</p><p>In the initial study design, PRR was selected as the primary endpoint based on prior study suggesting that the default settings of the BV-UFC system would have minimal impact on IDH frequency [<xref rid="bib20" ref-type="bibr">20</xref>]. However, during the preparatory phase, modifications to the BV-UFC settings led to a significant reduction in IDH frequency. Based on recommendations from peer reviewers, the study endpoints were revised. The primary endpoint was changed from PRR to the frequency of IDH, and PRR was designated as a secondary endpoint. This revision was approved by the ethics committee before implementation.</p></sec></sec><sec sec-type="results" id="sec4"><title>RESULTS</title><sec id="sec4-1"><title>Baseline characteristics</title><p>A total of 38 patients were enrolled in the study, but 5 were excluded before implementation due to consent withdrawal (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1), cerebral hemorrhage (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;2), death (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1) and sarcopenia-related hospital visit difficulties (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1). Two more patients did not complete the study due to sarcopenia-related dry weight adjustments (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1) and acute myocardial infarction (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1) (Fig.&#x000a0;<xref rid="fig2" ref-type="fig">2</xref>). Among the 31 remaining patients (90.3% on antihypertensive medication), no significant differences were observed in Kt/V urea, UFV or percentage of weight gain from dry weight before HD between the standard HD and HD with BV-UFC groups (Tables&#x000a0;<xref rid="tbl2" ref-type="table">2</xref> and&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>).</p><fig position="float" id="fig2"><label>Figure 2:</label><caption><p>Patient flow chart. This chart illustrates the progression of patients through the study. Out of 38 enrolled participants, 5 withdrew before the crossover phase due to consent withdrawal (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1), cerebral hemorrhage (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;2), death (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1) and sarcopenia-related hospital transfer (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;1). The remaining 33 patients entered the crossover phase, with two additional withdrawals due to complications. A total of 31 patients completed the study and were included in the final analysis.</p></caption><graphic xlink:href="sfaf141fig2" position="float"/></fig><table-wrap position="float" id="tbl2"><label>Table 2:</label><caption><p>Patients&#x02019; general characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Characteristics at study initiation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number of patients (men/women)</td><td rowspan="1" colspan="1">31 (8/23)</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">68.0&#x000a0;&#x000b1;&#x000a0;10.1</td></tr><tr><td rowspan="1" colspan="1">Group (A/B), <italic toggle="yes">n</italic>/<italic toggle="yes">n</italic></td><td rowspan="1" colspan="1">14/17</td></tr><tr><td colspan="2" align="left" rowspan="1">Disease, <italic toggle="yes">n</italic></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td rowspan="1" colspan="1">20</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chronic glomerulonephritis</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Nephrosclerosis</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ADPKD</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Others</td><td rowspan="1" colspan="1">1</td></tr><tr><td colspan="2" align="left" rowspan="1">Comorbidities, <italic toggle="yes">n</italic>/<italic toggle="yes">N</italic></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cardiovascular disease</td><td rowspan="1" colspan="1">20/31</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cerebrovascular disease</td><td rowspan="1" colspan="1">6/31</td></tr><tr><td colspan="2" align="left" rowspan="1">Medication, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Antihypertensive medicines</td><td rowspan="1" colspan="1">28 (90.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Renin-angiotensin system blocker</td><td rowspan="1" colspan="1">14 (45.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Calcium channel blocker</td><td rowspan="1" colspan="1">24 (77.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta blocker</td><td rowspan="1" colspan="1">8 (25.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Angiotensin receptor neprilysin inhibitor</td><td rowspan="1" colspan="1">5 (16.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Vitamin D analog</td><td rowspan="1" colspan="1">18 (58.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Erythropoiesis-stimulating agent</td><td rowspan="1" colspan="1">27 (77.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypoxia Inducible Factor Prolyl Hydroxylase</td><td rowspan="1" colspan="1">3 (9.7)</td></tr><tr><td colspan="2" align="left" rowspan="1">Laboratory findings</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hb (g/dL)</td><td rowspan="1" colspan="1">11.4&#x000a0;&#x000b1;&#x000a0;0.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;BUN (mg/dL)</td><td rowspan="1" colspan="1">54.47&#x000a0;&#x000b1;&#x000a0;10.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Serum creatinine (mg/dL)</td><td rowspan="1" colspan="1">10.1&#x000a0;&#x000b1;&#x000a0;2.1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Na (mEq/L)</td><td rowspan="1" colspan="1">139.8&#x000a0;&#x000b1;&#x000a0;3.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;K (mEq/L)</td><td rowspan="1" colspan="1">4.7&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cl (mEq/L)</td><td rowspan="1" colspan="1">105.0&#x000a0;&#x000b1;&#x000a0;3.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Ca (mg/dL)</td><td rowspan="1" colspan="1">8.5&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total protein (g/dL)</td><td rowspan="1" colspan="1">6.6&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Serum albumin (g/dL)</td><td rowspan="1" colspan="1">3.7&#x000a0;&#x000b1;&#x000a0;0.3</td></tr></tbody></table><table-wrap-foot><fn id="tb2fn1"><p>This table shows the baseline characteristics of study participants, including gender, age, primary disease (diabetes mellitus, chronic glomerulonephritis, nephrosclerosis, ADPKD, others), comorbidities (cardiovascular disease, cerebrovascular disease) and medications (antihypertensive drugs, renin&#x02013;angiotensin system blockers, calcium channel blockers, etc.). Additionally, laboratory findings such as Kt/V urea, blood urea nitrogen, and serum creatinine values for both standard HD and HD with BV-UFC are compared.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3:</label><caption><p>HD characteristics.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="6" align="left" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">HD</td><td colspan="5" align="left" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;HD duration (years)</td><td colspan="5" align="center" rowspan="1">8.5&#x000a0;&#x000b1;&#x000a0;5.2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dry weight (kg)</td><td colspan="5" align="center" rowspan="1">59.2&#x000a0;&#x000b1;&#x000a0;15.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HD times (min)</td><td rowspan="1" colspan="1">180</td><td rowspan="1" colspan="1">210</td><td rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1">360</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dialysate composition (mEq/L)</td><td align="center" colspan="2" rowspan="1">Na<sup>+</sup></td><td rowspan="1" colspan="1">K<sup>+</sup></td><td align="center" colspan="2" rowspan="1">Ca<sup>++</sup></td></tr><tr><td rowspan="1" colspan="1"/><td align="center" colspan="2" rowspan="1">140</td><td rowspan="1" colspan="1">2.0</td><td align="center" colspan="2" rowspan="1">2.75</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dialyzer type</td><td align="center" colspan="2" rowspan="1">CTA</td><td rowspan="1" colspan="1">PS</td><td align="center" colspan="2" rowspan="1">PAN AN69</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" colspan="2" rowspan="1">25</td><td rowspan="1" colspan="1">5</td><td align="center" colspan="2" rowspan="1">1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dialyzer membrane surface area (m<sup>2</sup>)</td><td align="center" colspan="5" rowspan="1">2.42&#x000a0;&#x000b1;&#x000a0;0.28</td></tr><tr><td rowspan="1" colspan="1">&#x02003;HD/HDF</td><td align="center" colspan="5" rowspan="1">23/8</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" colspan="2" rowspan="1">Standard HD</td><td align="center" rowspan="1" colspan="1">HD with BV-UFC</td><td align="center" colspan="2" rowspan="1">
<italic toggle="yes">P</italic>-value</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (total number of HD sessions)</td><td align="center" colspan="2" rowspan="1">186</td><td rowspan="1" colspan="1">186</td><td align="center" colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Treatment times (min)</td><td align="center" colspan="2" rowspan="1">231.6&#x000a0;&#x000b1;&#x000a0;2.8</td><td rowspan="1" colspan="1">231.8&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="center" colspan="2" rowspan="1">.82</td></tr><tr><td rowspan="1" colspan="1">Kt/V urea</td><td align="center" colspan="2" rowspan="1">1.51&#x000a0;&#x000b1;&#x000a0;0.47</td><td rowspan="1" colspan="1">1.49&#x000a0;&#x000b1;&#x000a0;0.042</td><td align="center" colspan="2" rowspan="1">.12</td></tr><tr><td rowspan="1" colspan="1">Pre-dialysis weight gain percentage (%)</td><td align="center" colspan="2" rowspan="1">3.09&#x000a0;&#x000b1;&#x000a0;0.12</td><td rowspan="1" colspan="1">3.17&#x000a0;&#x000b1;&#x000a0;0.10</td><td align="center" colspan="2" rowspan="1">.29</td></tr><tr><td rowspan="1" colspan="1">Ultrafiltration volume (L)</td><td align="center" colspan="2" rowspan="1">2.08&#x000a0;&#x000b1;&#x000a0;0.13</td><td rowspan="1" colspan="1">2.11&#x000a0;&#x000b1;&#x000a0;0.11</td><td align="center" colspan="2" rowspan="1">.61</td></tr><tr><td rowspan="1" colspan="1">Mean ultrafiltration rate (mL/hr)</td><td align="center" colspan="2" rowspan="1">540.6&#x000a0;&#x000b1;&#x000a0;14.5</td><td rowspan="1" colspan="1">548.1&#x000a0;&#x000b1;&#x000a0;12.3</td><td align="center" colspan="2" rowspan="1">.47</td></tr><tr><td rowspan="1" colspan="1">Blood flow (mL/min)</td><td align="center" colspan="2" rowspan="1">247.1&#x000a0;&#x000b1;&#x000a0;1.9</td><td rowspan="1" colspan="1">246.9&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="center" colspan="2" rowspan="1">.82</td></tr><tr><td rowspan="1" colspan="1">Pre-dialysis systolic BP (mmHg)</td><td align="center" colspan="2" rowspan="1">157.6&#x000a0;&#x000b1;&#x000a0;1.2</td><td rowspan="1" colspan="1">154.3&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="center" colspan="2" rowspan="1">.01</td></tr><tr><td rowspan="1" colspan="1">Post-dialysis systolic BP (mmHg)</td><td align="center" colspan="2" rowspan="1">148.6&#x000a0;&#x000b1;&#x000a0;1.5</td><td rowspan="1" colspan="1">147.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="center" colspan="2" rowspan="1">.62</td></tr></tbody></table><table-wrap-foot><fn id="tb3fn1"><p>This table presents detailed characteristics of the HD sessions conducted in this study, including session durations, types of dialyzers used, and treatment parameters for both standard HD and HD with BV-UFC.</p></fn><fn id="tb3fn2"><p>Dialyzer type: CTA, cellulose triacetate; PS, polysulfone; PAN AN69, polyacrylonitrile AN69.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4-2"><title>Primary outcome</title><p>The number of episodes with IHD per HD session was significantly different, 2.91&#x000a0;&#x000b1;&#x000a0;0.38 episodes in standard HD compared with 2.32&#x000a0;&#x000b1;&#x000a0;0.36 episodes in HD with BV-UFC (95% CI &#x02013;1.08 to 1.04; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.019). However, when evaluating the occurrence of IDH based on whether at least one event of systolic BP decrease &#x02265;20&#x000a0;mmHg occurred within a session, no significant difference was observed between standard HD (102/186 sessions, 54.8%) and HD with BV-UFC (105/186 sessions, 56.5%) (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.835) (Fig.&#x000a0;<xref rid="fig3" ref-type="fig">3</xref>).</p><fig position="float" id="fig3"><label>Figure 3:</label><caption><p>Primary outcomes. The figure compares the number of episodes of IDH per HD session between standard HD and HD with BV-UFC during different phases of the dialysis session and the number of dialysis sessions which at least one hypotensive event (systolic blood pressure decrease more than 20&#x000a0;mmHg), illustrating the effects of BV-UFC on hemodynamics. Bars indicate average&#x000a0;&#x000b1;&#x000a0;SE. <sup>*</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.05, <sup>**</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.01.</p></caption><graphic xlink:href="sfaf141fig3" position="float"/></fig></sec><sec id="sec4-3"><title>Secondary outcomes</title><p>The average PRR (mL/kg/h) over the entire HD session was significantly higher in HD with BV-UFC than in standard HD (95% CI 0.07&#x02013;0.75; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.019). The average PRR during the 0&#x02013;1&#x000a0;h and 1&#x02013;2&#x000a0;h after the initiation of HD was higher in HD with BV-UFC than in standard HD (95% CI 0.43 to 1.37; <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001) (95% CI 1.04&#x02013;2.07; <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001). There was no significant difference in the average PRR during 2&#x02013;3&#x000a0;h after initiating HD between the two groups (95% CI &#x02013;0.34 to 0.83; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.40). The average PRR during the 3&#x02013;4&#x000a0;h after the initiation of HD was significantly lower in HD with BV-UFC than in standard HD (95% CI 0.53&#x02013;1.86; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.001).</p><p>The target UFV was not achieved in 16 of the 186 standard HD sessions or in 9 of the 186 HD sessions in HD with BV-UFC. The achievement rate of the target UFV was significantly higher in the HD with BV-UFC group than that in the standard HD group (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001). There was no significant difference between the two groups in the number of treatment episodes for IDH (95% CI &#x02013;0.62 to &#x02013;0.30; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.46) (Fig.&#x000a0;<xref rid="fig4" ref-type="fig">4</xref>).</p><fig position="float" id="fig4"><label>Figure 4:</label><caption><p>Secondary outcomes. This figure depicts PRR, achieving the target UFV and treatment for IDH per HD session, comparing standard HD and HD with BV-UFC. Bars indicate the average&#x000a0;&#x000b1;&#x000a0;SE. <sup>*</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.05.</p></caption><graphic xlink:href="sfaf141fig4" position="float"/></fig></sec><sec id="sec4-4"><title>UF rate, PRR and &#x00394;BV during HD</title><p>Between 25 and 135&#x000a0;min, the UF rates with BV-UFC were considerably higher than those with standard HD. However, after 160&#x000a0;min, the UF rate was notably lower. The PRR was significantly higher in HD with BV-UFC compared with standard HD during the period from 30 to 130&#x000a0;min. Conversely, PRR was significantly lower in HD with BV-UFC than in standard HD at 180&#x000a0;min and during the period from 195 to 240&#x000a0;min. %&#x00394;BV was significantly lower in HD with BV-UFC compared with standard HD during the periods from 40 to 165&#x000a0;min, 80 to 170&#x000a0;min, and at 190&#x000a0;min. Conversely, %&#x00394;BV was significantly higher in HD with BV-UFC than in standard HD during the period from 235 to 240&#x000a0;min (Fig.&#x000a0;<xref rid="fig5" ref-type="fig">5</xref>).</p><fig position="float" id="fig5"><label>Figure 5:</label><caption><p>Changes in UF rate, PRR and &#x00394;BV during HD sessions. This figure shows the phases of UF rate, PRR and &#x00394;BV changes during HD sessions, including a constant UF rate period, a higher UF rate period, an automatic UF rate adjustment period and an automatic constant UF rate period. PRR values are expressed as 5-min averages (mL/kg/h), representing the mean plasma volume replenishment rate over successive time intervals. Bars indicate the average&#x000a0;&#x000b1;&#x000a0;SE. <sup>*</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.05, <sup>**</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.01.</p></caption><graphic xlink:href="sfaf141fig5" position="float"/></fig></sec><sec id="sec4-5"><title>BP and heart rate variation and %&#x00394;BV at the end of HD</title><p>Systolic BP at the start of HD was significantly lower in HD with BV-UFC than that in standard HD (95% CI 0.93 to &#x02013;5.71; <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.007). Furthermore, systolic BP from the start of HD up to 120&#x000a0;min (excluding the 20-min value) and 220&#x000a0;min after the start of HD was significantly lower in HD with BV-UFC than in standard HD. Diastolic BP was significantly lower in the HD with BV-UFC group than in the standard HD group at 60 and 80&#x000a0;min after the start of HD. No significant differences in heart rate were observed between the two groups throughout the HD period. At the end of HD, %&#x00394;BV was &#x02013;6.35&#x000a0;&#x000b1;&#x000a0;0.21% (mean&#x000a0;&#x000b1;&#x000a0;SE) in HD with BV-UFC and &#x02013;7.09&#x000a0;&#x000b1;&#x000a0;0.26% in standard HD. Thus, %&#x00394;BV at the end of HD was significantly higher in HD with BV-UFC compared with the standard HD (95% CI 0.35 to 1.12; <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.001) (Fig.&#x000a0;<xref rid="fig6" ref-type="fig">6</xref>).</p><fig position="float" id="fig6"><label>Figure 6:</label><caption><p>BP and heart rate variation and %&#x00394;BV at the end of HD. This figure illustrates the variations in systolic BP, diastolic BP, heart rate and %&#x00394;BV at the end of HD between standard HD and HD with BV-UFC. Bars indicate the average&#x000a0;&#x000b1;&#x000a0;SE. <sup>*</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.05, <sup>**</sup><italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;.01.</p></caption><graphic xlink:href="sfaf141fig6" position="float"/></fig></sec></sec><sec sec-type="discussion" id="sec5"><title>DISCUSSION</title><p>In this study, we extended the third phase of HD with BV-UFC beyond default settings to examine its hemodynamic effects. It is possible that the number of IDH episodes is reduced due to the use of automatic UF adjustments. Additionally, BV-UFC improved target UFV achievement compared with standard HD. To our knowledge, this is the first study to show IDH reduction through BV-based UF regulation.</p><p>Currently, there is no universally accepted definition for IDH. According to the Kidney Disease Outcomes Quality Initiative (KDOQI) and European Best Practice Guidelines, IDH is defined as a decrease in systolic BP of &#x02265;20&#x000a0;mmHg or a decrease in MAP of 10&#x000a0;mmHg accompanied by clinical symptoms requiring nursing interventions [<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>]. Such a reduction in systolic BP of &#x02265;20&#x000a0;mmHg or MAP of &#x02265;10&#x000a0;mmHg has been reported in 68.9%&#x02013;77.7% of cases [<xref rid="bib23" ref-type="bibr">3</xref>, 2<xref rid="bib3" ref-type="bibr">3</xref>]. Recently, IDH was often defined as &#x0201c;a systolic BP of less than 90&#x000a0;mmHg during a session&#x0201d; and &#x0201c;a nadir of less than 100&#x000a0;mmHg or &#x0003c;90 or 100&#x000a0;mmHg if the initial systolic BP was &#x0003c;160&#x000a0;mmHg or &#x0003e;160&#x000a0;mmHg, respectively,&#x0201d; as these definitions are associated with increased patient mortality [<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>]. However, episodes meeting these definitions were extremely rare in our study population, with only 3 occurrences in 186 standard HD sessions and 1 occurrence in 186 BV-UFC sessions for the former definition, and 3 occurrences in standard sessions and 2 in BV-UFC-guided sessions for the latter. This rarity is likely due to the selection of outpatient dialysis patients with relatively stable overall conditions, who are less prone to severe hemodynamic instability.</p><p>Several factors contribute to the development of IDH, including excessive UF rates, chronic heart failure and inappropriate dry weight settings [<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib26" ref-type="bibr">26</xref>]. Notably, both IDH and BP variability during HD considerably impact life expectancy, and an increase in the incidence of cardiovascular events in HD patients [<xref rid="bib2" ref-type="bibr">2&#x02013;4</xref>] IDH is prevalent among HD patients and represents a critical issue in HD treatment with substantial influences on patient prognosis. Effective strategies for the prevention of IDH include the use of hemodiafiltration (HDF) [<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>], intermittent infusion hemodiafiltration [<xref rid="bib29" ref-type="bibr">29</xref>], high-volume hemodiafiltration [<xref rid="bib30" ref-type="bibr">30</xref>], cooler dialysate temperature [<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib31" ref-type="bibr">31</xref>] and vasopressors, such as midodrine [<xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>], have demonstrated efficacy in reducing IDH episodes.</p><p>Modern HD devices, such as the one used in this study [Nikkiso Co., Ltd (equipped with a BV-UFC system)] [<xref rid="bib20" ref-type="bibr">20</xref>] are capable of noninvasive BV monitoring with high accuracy by optically measuring variations in hematocrit, the primary blood component that determines total protein concentration [<xref rid="bib14" ref-type="bibr">14&#x02013;16</xref>, <xref rid="bib34" ref-type="bibr">34</xref>]. The system automatically adjusts the UF rate every 2&#x000a0;min based on real-time BV measurements from a built-in BV monitor. If %&#x00394;BV falls below the target curve, the UF rate is reduced; if it drops more than 3% below, UF is temporarily suspended. Conversely, if %&#x00394;BV exceeds the target, the UF rate is increased above the constant rate. This constant rate is calculated as the remaining UF volume divided by the remaining HD time. Thus, the BV-UFC system makes precise UF adjustments based on BV, which are challenging to perform manually.</p><p>To date, only one study has compared the utility of BV-UFC with standard HD [<xref rid="bib20" ref-type="bibr">20</xref>]. This crossover trial was conducted to compare standard HD and HD with BV-UFC. Similar to the present study, a considerable difference in &#x00394;BV was observed at the end of dialysis. However, no substantial differences were found in the frequency of IDH or achievement rate of the target UFV. We hypothesized that the BV-UFC system in its default settings would likely have a minimal impact on IDH frequency and therefore focused on PRR as a more direct measure of the system's effectiveness in optimizing plasma refilling dynamics. However, adjustments made during the preparatory phase revealed unexpected benefits in IDH reduction, leading to the revision of the primary endpoint. This highlights the importance of dynamic assessment during preparatory phases and suggests further exploration of BV-UFC settings in clinical practice.</p><p>In this study, we compared mean PRR during HD between standard HD and HD with BV-UFC to assess hemodynamic changes. Although mean UFV per session was similar in both groups, mean PRR was higher in the BV-UFC group throughout HD and especially in the first 2&#x000a0;h. This increase is likely due to the BV-UFC's automatic UF rate increase during the early phase when excess fluid volume is higher [<xref rid="bib35" ref-type="bibr">35</xref>]. Changing the settings from the default configuration to those used in this study unexpectedly resulted in a lower frequency of IDH in the HD with BV-UFC compared with standard HD (Fig.&#x000a0;<xref rid="fig3" ref-type="fig">3</xref>), contrary to our initial expectations and prior study. This difference may be due to the shortened second period (10&#x000a0;min instead of 60&#x000a0;min) and the extended third period in our study, allowing earlier automatic UF adjustments based on BV and PRR. In the previous study, a higher UF rate in the prolonged second period led to greater drops in systolic BP and %&#x00394;BV, likely impacting hemodynamics. Here, reducing the UF rate in the second part and extending the third part enabled better plasma refilling, leading to improved intravascular volume maintenance and a lower frequency of IDH. Notably, UFV was similar between groups, but plasma refilling was significantly greater in the BV-UFC group. In the BV-UFC group, the target UFV was achieved even with the UF rate reduced to 50% during the fourth phase. For patients with sufficient UF progress, the target UFV or a value very close to it was typically reached by the end of the third phase. Consequently, the remaining UFV during the fourth phase was minimal, allowing participants to achieve a dry weight within &#x000b1;0.3&#x000a0;kg of the target in the majority of sessions.</p><p>In our study, we evaluated IDH occurrence using two different approaches: (i) the proportion of sessions with at least one IDH event (systolic BP decrease &#x02265;20&#x000a0;mmHg) and (ii) the number of IDH episodes per session. While no significant difference was observed in the proportion of IDH sessions between standard HD and HD with BV-UFC (54.8% vs 56.5%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.8353), the number of IDH episodes per session was significantly lower in the BV-UFC group (2.91&#x000a0;&#x000b1;&#x000a0;0.38 vs 2.32&#x000a0;&#x000b1;&#x000a0;0.36, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;.019). These findings suggest that BV-UFC may not completely prevent IDH, but it could reduce its recurrence within a session, contributing to improved hemodynamic stability. Previous studies have also highlighted the importance of evaluating IDH frequency rather than session-based IDH occurrence alone. Studies by Rootjes <italic toggle="yes">et al</italic>. (2022), Bullen <italic toggle="yes">et al</italic>. (2019) and Chesterton <italic toggle="yes">et al</italic>. (2009) demonstrated that interventions such as high-volume hemodiafiltration and cool dialysate effectively reduce the overall frequency of IDH episodes [<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>]. These findings support the hypothesis that strategies focusing on minimizing IDH recurrence may enhance hemodynamic stability during dialysis. This distinction between session-based IDH occurrence and IDH frequency may be crucial in assessing the clinical relevance of BV-UFC and other interventions. Further studies are needed to explore whether a reduction in IDH recurrence per session translates to improved long-term outcomes for HD patients.</p><p>The higher %&#x00394;BV observed at the end of HD in the BV-UFC group can be attributed to the system's dynamic adjustment of UF rates. By reducing the UF rate during the later phases of dialysis, particularly when the amount of excess body water was low, the BV-UFC system effectively maintained hemodynamic stability while minimizing the risk of excessive fluid removal. These findings highlight the potential advantages of BV-UFC in preventing hemodynamic complications during HD.</p><p>In the present study, systolic BP was significantly lower in HD with BV-UFC than in standard HD from the start of sessions. This result differs from those of a previous study [<xref rid="bib20" ref-type="bibr">20</xref>]. Extending the duration of HD and lowering the UF rate during HD can reduce the incidence of IDH and improve control of BP [<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib38" ref-type="bibr">38</xref>]. It has been also reported that shorter dialysis durations with higher UF rates are associated with increased BP and a higher frequency of IDH [<xref rid="bib28" ref-type="bibr">28</xref>]. A high UF rate may be associated with sympathetic nervous system activation, renin&#x02013;angiotensin system activation, endothelial stiffness [<xref rid="bib39" ref-type="bibr">39</xref>]. In this study, entering the third stage earlier likely prevented excessive UF in the early phase of HD. Reducing the UF rate in the later phase may lessen physiological stress and improve BP control. If BV-UFC has similar BP benefits as extended HD sessions, it could enhance the long-term prognosis for HD patients.</p><p>Recently, Nikkiso's HEMOMASTER system combines BV monitoring and feedback controls. While both systems of BV-UFC and HEMOMASTER system are developed by Nikkiso and are part of their dialysis equipment, they differ in functionality and design. HEMOMASTER system calculates the &#x00394;BV decrease rate per liter of UF, and healthcare providers select from five target lines ranging from gentle to steep. Gentler lines have been associated with fewer adverse effects such as IDH, sweating and fatigue [<xref rid="bib40" ref-type="bibr">40</xref>]. Similar to BV-UFC, HEMOMASTER features a constant UF rate period, but lacks a higher UF rate period. Incorporating gentler target lines, as suggested by HEMOMASTER, may have further reduced IDH in this study.</p><p>The findings of this study suggest that BV-UFC may contribute to improved hemodynamic stability during hemodialysis by reducing the recurrence of IDH episodes. Although the proportion of dialysis sessions with at least one IDH event did not differ significantly between groups, BV-UFC significantly reduced the number of IDH episodes per session. This indicates that BV-UFC may help mitigate recurrent hypotensive episodes rather than completely preventing IDH occurrence. Further research is needed to determine whether this reduction in IDH frequency translates into improved patient outcomes, such as cardiovascular protection and better long-term fluid management. Future studies should also assess the efficacy of BV-UFC in populations at higher risk of IDH, such as hospitalized patients or those with compromised cardiovascular function.</p><p>The study has several limitations. IDH was assessed only by systolic BP or MAP reductions, excluding clinical symptoms. This study has the exclusion of subjective clinical symptoms, such as sweating and fatigue, from the analysis. While these symptoms were observed during dialysis sessions, they were not systematically recorded or analyzed due to their subjective nature. Instead, the study focused on objective data that could be quantified and reliably measured, such as the frequency of IDH and BP changes. One limitation of this study is the evaluation of IDH incidence using BP measurements at 20-min intervals, which may underestimate the actual frequency of IDH due to missed episodes between measurements. This limitation is consistent with findings from Chaara <italic toggle="yes">et al</italic>. [<xref rid="bib41" ref-type="bibr">41</xref>], which emphasize the need for more frequent BP monitoring to accurately capture IDH events. Hospitalized patients with fluctuating dry weight were not included, and the short-term crossover design did not assess long-term outcomes. Home BP monitoring was also lacking, despite lower systolic BP at the start of HD with BV-UFC. Future studies should address these gaps to better evaluate BV-UFC's effectiveness. This study also did not evaluate the effectiveness of BV-UFC under conditions such as HD with a cold dialysate temperature (e.g. 35.5&#x000b0;C) or high-volume hemodiafiltration (total convective volume &#x0003e;23&#x000a0;L/session). These conditions may influence plasma refilling dynamics and UF outcomes, and further studies are needed to validate the efficacy of BV-UFC in these settings.</p><p>This study shows that adjusting the UF rate automatically based on BV reduces IDH frequency while achieving similar UFV as standard HD within the same treatment time. It is the first to report that automatic UF adjustment can reduce IDH frequency while maintaining safety compared with standard HD.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data"><label>sfaf141_Supplemental_File</label><media xlink:href="sfaf141_supplemental_file.docx"/></supplementary-material></sec></body><back><ack id="ack1"><title>ACKNOWLEDGEMENTS</title><p>We express our sincere gratitude to the staff at Nikkiso Co., Ltd for their invaluable guidance in helping us understand the mechanics of the BV-UFC system. Their expertise and support were instrumental in the successful implementation of this study.</p></ack><sec id="sec7"><title>FUNDING</title><p>This research received no external funding.</p></sec><sec id="sec8"><title>AUTHORS&#x02019; CONTRIBUTIONS</title><p>Conceptualization: S.H., S.Y. Formal analysis: S.H., S.Y. Investigation: S.H., M.H., S.F., S.Y. Methodology: S.H., S.F., S.Y. Project administration: S.H. Supervision: S.Y. Visualization: S.H. Writing&#x02014;original draft preparation: S.H., S.Y. Writing&#x02014;review and editing: S.Y.</p></sec><sec sec-type="data-availability" id="sec9"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author (S.H.), upon reasonable request.</p></sec><sec sec-type="COI-statement" id="sec10"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest to disclose.</p></sec><ref-list id="ref1"><title>REFERENCES</title><ref id="bib1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kanbay</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Ertuglu</surname> &#x000a0;<given-names>LA</given-names></string-name>, <string-name><surname>Afsar</surname> &#x000a0;<given-names>B</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>An update review of intradialytic hypotension: concept, risk factors, clinical implications and management</article-title>. <source>Clin Kidney J</source> &#x000a0;<year>2020</year>;<volume>13</volume>:<fpage>981</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/ckj/sfaa078</pub-id><pub-id pub-id-type="pmid">33391741</pub-id>
</mixed-citation></ref><ref id="bib2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tisl&#x000e9;r</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Ak&#x000f3;csi</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Borb&#x000e1;s</surname> &#x000a0;<given-names>B</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2003</year>;<volume>18</volume>:<fpage>2601</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfg450</pub-id><pub-id pub-id-type="pmid">14605284</pub-id>
</mixed-citation></ref><ref id="bib3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Flythe</surname> &#x000a0;<given-names>JE</given-names></string-name>, <string-name><surname>Xue</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Lynch</surname> &#x000a0;<given-names>KE</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Association of mortality risk with various definitions of intradialytic hypotension</article-title>. <source>J Am Soc Nephrol</source> &#x000a0;<year>2015</year>;<volume>26</volume>:<fpage>724</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014020222</pub-id><pub-id pub-id-type="pmid">25270068</pub-id>
</mixed-citation></ref><ref id="bib4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liu</surname> &#x000a0;<given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname> &#x000a0;<given-names>W</given-names></string-name>, <string-name><surname>Wu</surname> &#x000a0;<given-names>X</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Intra-dialytic blood pressure variability is a greater predictor of cardiovascular events in hemodialysis patients</article-title>. <source>BMC Nephrol</source> &#x000a0;<year>2023</year>;<volume>24</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1186/s12882-023-03162-w</pub-id><pub-id pub-id-type="pmid">36597041</pub-id>
</mixed-citation></ref><ref id="bib5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Raine</surname> &#x000a0;<given-names>AEG.</given-names></string-name>
</person-group> &#x000a0;<article-title>The susceptible patient</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>1996</year>;<volume>11</volume>:<fpage>6</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/11.supp2.6</pub-id>. <comment>10.1093/ndt/16.8.1657</comment></mixed-citation></ref><ref id="bib6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sato</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Horigome</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Chiba</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Autonomic insufficiency as a factor contributing to dialysis-induced hypotension</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2001</year>;<volume>16</volume>:<fpage>1657</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/11.supp2.11</pub-id><pub-id pub-id-type="pmid">11477170</pub-id>
</mixed-citation></ref><ref id="bib7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Leunissen</surname> &#x000a0;<given-names>KML</given-names></string-name>, <string-name><surname>Kooman</surname> &#x000a0;<given-names>JP</given-names></string-name>, <string-name><surname>Van Kuijk</surname> &#x000a0;<given-names>W</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Preventing haemodynamic instability in patients at risk for intra-dialytic hypotension</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>1996</year>;<volume>11</volume>:<fpage>11</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00881.x</pub-id></mixed-citation></ref><ref id="bib8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Flythe</surname> &#x000a0;<given-names>JE</given-names></string-name>, <string-name><surname>Kimmel</surname> &#x000a0;<given-names>SE</given-names></string-name>, <string-name><surname>Brunelli</surname> &#x000a0;<given-names>SM.</given-names></string-name></person-group> &#x000a0;<article-title>Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality</article-title>. <source>Kidney Int</source> &#x000a0;<year>2011</year>;<volume>79</volume>:<fpage>250</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2010.383</pub-id><pub-id pub-id-type="pmid">20927040</pub-id>
</mixed-citation></ref><ref id="bib9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pillon</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Piccoli</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Lowrie</surname> &#x000a0;<given-names>EG</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis</article-title>. <source>Kidney Int</source> &#x000a0;<year>2004</year>;<volume>66</volume>:<fpage>1266</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00881.x</pub-id><pub-id pub-id-type="pmid">15327426</pub-id>
</mixed-citation></ref><ref id="bib10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Termorshuizen</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Dekker</surname> &#x000a0;<given-names>FW</given-names></string-name>, <string-name><surname>Van Manen</surname> &#x000a0;<given-names>JG</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of dialysis (NECOSAD)-2</article-title>. <source>J Am Soc Nephrol</source> &#x000a0;<year>2004</year>;<volume>15</volume>:<fpage>1061</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1097/01.ASN.0000117976.29592.93</pub-id><pub-id pub-id-type="pmid">15034110</pub-id>
</mixed-citation></ref><ref id="bib11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Daugirdas</surname> &#x000a0;<given-names>JT.</given-names></string-name>
</person-group> &#x000a0;<article-title>Pathophysiology of dialysis hypotension: an update</article-title>. <source>Am J Kidney Dis</source> &#x000a0;<year>2001</year>;<volume>38</volume>:<fpage>S11</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1053/ajkd.2001.28090</pub-id></mixed-citation></ref><ref id="bib12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schroeder</surname> &#x000a0;<given-names>KL</given-names></string-name>, <string-name><surname>Sallustio</surname> &#x000a0;<given-names>JE</given-names></string-name>, <string-name><surname>Ross</surname> &#x000a0;<given-names>EA.</given-names></string-name></person-group> &#x000a0;<article-title>Continuous haematocrit monitoring during intradialytic hypotension: precipitous decline in plasma refill rates</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2004</year>;<volume>19</volume>:<fpage>652</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfg590</pub-id><pub-id pub-id-type="pmid">14767022</pub-id>
</mixed-citation></ref><ref id="bib13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Saran</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Bragg-Gresham</surname> &#x000a0;<given-names>JL</given-names></string-name>, <string-name><surname>Levin</surname> &#x000a0;<given-names>NW</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS</article-title>. <source>Kidney Int</source> &#x000a0;<year>2006</year>;<volume>69</volume>:<fpage>1222</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5000186</pub-id><pub-id pub-id-type="pmid">16609686</pub-id>
</mixed-citation></ref><ref id="bib14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mancini</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Santoro</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Spongano</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Continuous on-line optical absorbance recording of blood volume changes during hemodialysis</article-title>. <source>Artif. Organs</source> &#x000a0;<year>1993</year>;<volume>17</volume>:<fpage>691</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1111/j.1525-1594.1993.tb00616.x</pub-id><pub-id pub-id-type="pmid">8215949</pub-id>
</mixed-citation></ref><ref id="bib15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Yoshida</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Ando</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Ando</surname> &#x000a0;<given-names>Y</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>A new device to monitor blood volume in hemodialysis patients</article-title>. <source>Ther Apher Dial</source> &#x000a0;<year>2010</year>;<volume>14</volume>:<fpage>560</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/j.1744-9987.2010.00845.x</pub-id><pub-id pub-id-type="pmid">21118363</pub-id>
</mixed-citation></ref><ref id="bib16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dong</surname> &#x000a0;<given-names>Z</given-names></string-name>, <string-name><surname>Fuentes</surname> &#x000a0;<given-names>LR</given-names></string-name>, <string-name><surname>Rao</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Closed loop ultrafiltration feedback control in hemodialysis: a narrative review</article-title>. <source>Toxins (Basel)</source> &#x000a0;<year>2024</year>;<volume>16</volume>:<fpage>1</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.3390/toxins16080351</pub-id></mixed-citation></ref><ref id="bib17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kolben</surname> &#x000a0;<given-names>Y</given-names></string-name>, <string-name><surname>Gork</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Peled</surname> &#x000a0;<given-names>D</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Continuous monitoring of advanced hemodynamic parameters during hemodialysis demonstrated early variations in patients experiencing intradialytic hypotension</article-title>. <source>Biomedicines</source> &#x000a0;<year>2024</year>;<volume>12</volume>:<fpage>1177</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines12061177</pub-id><pub-id pub-id-type="pmid">38927384</pub-id>
</mixed-citation></ref><ref id="bib18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jongejan</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Gelinck</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>van Geloven</surname> &#x000a0;<given-names>N</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Effect of absolute blood volume measurement&#x02013;guided fluid management on the incidence of intradialytic hypotension-associated events: a randomised controlled trial</article-title>. <source>Clin Kidney J</source> &#x000a0;<year>2024</year>;<volume>17</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/ckj/sfae128</pub-id><pub-id pub-id-type="pmid">39583140</pub-id>
</mixed-citation></ref><ref id="bib19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Reddan</surname> &#x000a0;<given-names>DN</given-names></string-name>, <string-name><surname>Szczech</surname> &#x000a0;<given-names>LA</given-names></string-name>, <string-name><surname>Hasselblad</surname> &#x000a0;<given-names>V</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial</article-title>. <source>J Am Soc Nephrol</source> &#x000a0;<year>2005</year>;<volume>16</volume>:<fpage>2162</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2004121053</pub-id><pub-id pub-id-type="pmid">15930095</pub-id>
</mixed-citation></ref><ref id="bib20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ookawara</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Ito</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Uchida</surname> &#x000a0;<given-names>T</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Hemodialysis crossover study using a relative blood volume change-guided ultrafiltration control compared with standard hemodialysis: the BV-UFC study</article-title>. <source>Ren Replace Ther</source> &#x000a0;<year>2020</year>;<volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/s41100-020-00295-8</pub-id></mixed-citation></ref><ref id="bib21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>K/DOQI Workgroup</collab>
</person-group>. <article-title>K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients</article-title>. <source>Am J Kidney Dis</source> &#x000a0;<year>2005</year>;<volume>45</volume>:<fpage>S1</fpage>&#x02013;<lpage>153</lpage>.</mixed-citation></ref><ref id="bib22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kooman</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Basci</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Pizzarelli</surname> &#x000a0;<given-names>F</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>EBPG guideline on haemodynamic instability</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2007</year>;<volume>22</volume>:<fpage>22</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfm019</pub-id></mixed-citation></ref><ref id="bib23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kuipers</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Oosterhuis</surname> &#x000a0;<given-names>JK</given-names></string-name>, <string-name><surname>Krijnen</surname> &#x000a0;<given-names>WP</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Prevalence of intradialytic hypotension, clinical symptoms and nursing interventions&#x02014;A three-months, prospective study of 3818 haemodialysis sessions dialysis and transplantation</article-title>. <source>BMC Nephrol</source> &#x000a0;<year>2016</year>;<volume>17</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1186/s12882-016-0231-9</pub-id><pub-id pub-id-type="pmid">26727891</pub-id>
</mixed-citation></ref><ref id="bib24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Flythe</surname> &#x000a0;<given-names>JE</given-names></string-name>, <string-name><surname>Xue</surname> &#x000a0;<given-names>H</given-names></string-name>, <string-name><surname>Lynch</surname> &#x000a0;<given-names>KE</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Association of mortality risk with various definitions of intradialytic hypotension</article-title>. <source>J Am Soc Nephrol</source> &#x000a0;<year>2015</year>;<volume>26</volume>:<fpage>724</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014020222</pub-id><pub-id pub-id-type="pmid">25270068</pub-id>
</mixed-citation></ref><ref id="bib25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chou</surname> &#x000a0;<given-names>JA</given-names></string-name>, <string-name><surname>Streja</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Nguyen</surname> &#x000a0;<given-names>DV</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2018</year>;<volume>33</volume>:<fpage>149</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfx037</pub-id><pub-id pub-id-type="pmid">28444336</pub-id>
</mixed-citation></ref><ref id="bib26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brennan</surname> &#x000a0;<given-names>JM</given-names></string-name>, <string-name><surname>Ronan</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Goonewardena</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Handcarried ultrasound measurement of the inferior vena cava for assessment of intravascular volume status in the outpatient hemodialysis clinic</article-title>. <source>Clin J Am Soc Nephrol</source> &#x000a0;<year>2006</year>;<volume>1</volume>:<fpage>749</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.00310106</pub-id><pub-id pub-id-type="pmid">17699282</pub-id>
</mixed-citation></ref><ref id="bib27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Donauer</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Schweiger</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Rumberger</surname> &#x000a0;<given-names>B</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2003</year>;<volume>18</volume>:<fpage>1616</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfg206</pub-id><pub-id pub-id-type="pmid">12897103</pub-id>
</mixed-citation></ref><ref id="bib28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Locatelli</surname> &#x000a0;<given-names>F</given-names></string-name>, <string-name><surname>Altieri</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Andrulli</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD</article-title>. <source>J Am Soc Nephrol</source> &#x000a0;<year>2010</year>;<volume>21</volume>:<fpage>1798</fpage>&#x02013;<lpage>807</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2010030280</pub-id><pub-id pub-id-type="pmid">20813866</pub-id>
</mixed-citation></ref><ref id="bib29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koda</surname> &#x000a0;<given-names>Y</given-names></string-name>, <string-name><surname>Aoike</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Hasegawa</surname> &#x000a0;<given-names>S</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Feasibility of intermittent back-filtrate infusion hemodiafiltration to reduce intradialytic hypotension in patients with cardiovascular instability: a pilot study</article-title>. <source>Clin Exp Nephrol</source> &#x000a0;<year>2017</year>;<volume>21</volume>:<fpage>324</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1007/s10157-016-1270-z</pub-id><pub-id pub-id-type="pmid">27125432</pub-id>
</mixed-citation></ref><ref id="bib30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rootjes</surname> &#x000a0;<given-names>PA</given-names></string-name>, <string-name><surname>Chaara</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>de Roij van Zuijdewijn</surname> &#x000a0;<given-names>CLM</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>High-volume hemodiafiltration and cool hemodialysis have a beneficial effect on intradialytic hemodynamics: a randomized cross-over trial of four intermittent dialysis strategies</article-title>. <source>Kidney Int Rep</source> &#x000a0;<year>2022</year>;<volume>7</volume>:<fpage>1980</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ekir.2022.06.021</pub-id><pub-id pub-id-type="pmid">36090495</pub-id>
</mixed-citation></ref><ref id="bib31"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Zoccali</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Tripepi</surname> &#x000a0;<given-names>G</given-names></string-name>, <string-name><surname>Neri</surname> &#x000a0;<given-names>L</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Effectiveness of cold HD for the prevention of HD hypotension and mortality in the general HD population</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2023</year>;<volume>38</volume>:<fpage>1700</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfad003</pub-id><pub-id pub-id-type="pmid">36649682</pub-id>
</mixed-citation></ref><ref id="bib32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Prakash</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Garg</surname> &#x000a0;<given-names>AX</given-names></string-name>, <string-name><surname>Heidenheim</surname> &#x000a0;<given-names>AP</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2004</year>;<volume>19</volume>:<fpage>2553</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfh420</pub-id><pub-id pub-id-type="pmid">15280522</pub-id>
</mixed-citation></ref><ref id="bib33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Brunelli</surname> &#x000a0;<given-names>SM</given-names></string-name>, <string-name><surname>Cohen</surname> &#x000a0;<given-names>DE</given-names></string-name>, <string-name><surname>Marlowe</surname> &#x000a0;<given-names>G</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>The impact of midodrine on outcomes in patients with intradialytic hypotension</article-title>. <source>Am J Nephrol</source> &#x000a0;<year>2018</year>;<volume>48</volume>:<fpage>381</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1159/000494806</pub-id><pub-id pub-id-type="pmid">30423552</pub-id>
</mixed-citation></ref><ref id="bib34"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Johner</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Chamney</surname> &#x000a0;<given-names>PW</given-names></string-name>, <string-name><surname>Schneditz</surname> &#x000a0;<given-names>D</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Evaluation of an ultrasonic blood volume monitor</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>1998</year>;<volume>13</volume>:<fpage>2098</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/13.8.2098</pub-id><pub-id pub-id-type="pmid">9719173</pub-id>
</mixed-citation></ref><ref id="bib35"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mitsides</surname> &#x000a0;<given-names>N</given-names></string-name>, <string-name><surname>Pietribiasi</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Waniewski</surname> &#x000a0;<given-names>J</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Transcapillary refilling rate and its determinants during haemodialysis with standard and high ultrafiltration rates</article-title>. <source>Am J Nephrol</source> &#x000a0;<year>2019</year>;<volume>50</volume>:<fpage>133</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1159/000501407</pub-id><pub-id pub-id-type="pmid">31288231</pub-id>
</mixed-citation></ref><ref id="bib36"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bullen</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Rifkin</surname> &#x000a0;<given-names>D</given-names></string-name>, <string-name><surname>Trzebinska</surname> &#x000a0;<given-names>D.</given-names></string-name></person-group> &#x000a0;<article-title>Individualized cool dialysate as an effective therapy for intradialytic hypotension and hemodialysis patients&#x02019; perception</article-title>. <source>Ther Apher Dial</source> &#x000a0;<year>2019</year>;<volume>23</volume>:<fpage>145</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/1744-9987.12761</pub-id><pub-id pub-id-type="pmid">30226300</pub-id>
</mixed-citation></ref><ref id="bib37"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chesterton</surname> &#x000a0;<given-names>LJ</given-names></string-name>, <string-name><surname>Selby</surname> &#x000a0;<given-names>NM</given-names></string-name>, <string-name><surname>Burton</surname> &#x000a0;<given-names>JO</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Cool dialysate reduces asymptomatic intradialytic hypotension and increases baroreflex variability</article-title>. <source>Hemodial Int</source> &#x000a0;<year>2009</year>;<volume>13</volume>:<fpage>189</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1111/j.1542-4758.2009.00355.x</pub-id><pub-id pub-id-type="pmid">19432693</pub-id>
</mixed-citation></ref><ref id="bib38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tandon</surname> &#x000a0;<given-names>T</given-names></string-name>, <string-name><surname>Sinha</surname> &#x000a0;<given-names>AD</given-names></string-name>, <string-name><surname>Agarwal</surname> &#x000a0;<given-names>R.</given-names></string-name></person-group> &#x000a0;<article-title>Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2013</year>;<volume>28</volume>:<fpage>1562</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfs597</pub-id><pub-id pub-id-type="pmid">23348881</pub-id>
</mixed-citation></ref><ref id="bib39"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kim</surname> &#x000a0;<given-names>IS</given-names></string-name>, <string-name><surname>Kim</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Yoo</surname> &#x000a0;<given-names>TH</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Diagnosis and treatment of hypertension in dialysis patients: a systematic review</article-title>. <source>Clin Hypertens</source> &#x000a0;<year>2023</year>;<volume>29</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1186/s40885-023-00240-x</pub-id><pub-id pub-id-type="pmid">36593518</pub-id>
</mixed-citation></ref><ref id="bib40"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Xu</surname> &#x000a0;<given-names>Z</given-names></string-name>, <string-name><surname>Liang</surname> &#x000a0;<given-names>G</given-names></string-name>, <string-name><surname>Wang</surname> &#x000a0;<given-names>Y</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>Effectiveness and safety of HAEMOMASTER system in hemodialysis patients</article-title>. <source>Altern Ther Health Med</source> &#x000a0;<year>2023</year>;<volume>29</volume>.</mixed-citation></ref><ref id="bib41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chaara</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Rootjes</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Bergtop</surname> &#x000a0;<given-names>M</given-names></string-name> &#x000a0;<etal>et al.</etal></person-group> &#x000a0;<article-title>#672 Intradialytic hypotension and adverse symptoms are not related</article-title>. <source>Nephrol Dial Transplant</source> &#x000a0;<year>2024</year>;<volume>39</volume>:<fpage>gfae069&#x02013;e0760&#x02013;672</fpage>.<pub-id pub-id-type="doi">10.1093/ndt/gfae069.760</pub-id></mixed-citation></ref></ref-list></back></article>